The Implant Outlives the Company. Who Keeps the Body Working?

A company can shut down in an afternoon. The device it put inside a person may remain there for years. Between those two clocks sits a problem the technology industry is still inclined to describe as customer support, as though the customer can put the product in a drawer and buy something else. An implanted system makes that language inadequate. Its failure can change how someone moves, communicates, experiences symptoms, or organizes an ordinary day.

False Normal supplies the starting question through proprietary augmentation and disputed authority over treatment. The novel's extraordinary hardware is fiction. The dependency underneath it is familiar: a person may possess the physical device while somebody else controls the tools required to keep it useful. Cyberdelia's angle is the service architecture. Before asking how powerful an implant can become, ask what happens to its wearer when the organization behind it becomes unavailable.

A 2024 systematic review and consensus statement in JAMA Network Open proposes a definition of implanted neurological device abandonment that includes failures of informed consent, reasonable medical and technical support, and responses to immediate needs. The authors treat responsibility as something that persists beyond implantation. This is an expert framework, not a universal law or proof that every device company behaves alike. It nevertheless gives a name to a failure that a conventional product warranty barely touches.

The infrastructure around an implant is larger than the object. A clinician may need a programmer to adjust parameters. A wearer may rely on an external processor, charger, fitted accessory, or software version. Diagnostic records may be necessary to understand a fault. A replacement component may have to be compatible with a particular generation of hardware. If any one of these dependencies becomes unavailable, a perfectly intact implanted component can become practically unusable. Reliability belongs to the whole service chain.

That makes the ordinary startup story uncomfortable. Venture finance expects companies to pivot, consolidate, run out of money, and discontinue unsuccessful lines. Those events are tolerable in many markets because customers can migrate. An implant wearer cannot necessarily migrate by exporting a folder. Changing systems may involve specialist care, a new procedure, additional training, or accepting a loss of function. A market exit becomes a clinical continuity problem even when nobody has hacked anything.

Security complicates the response. It is tempting to say that wearers should simply receive every programming key and unrestricted access. But the same interface that makes maintenance possible may also control safety-critical settings. Removing authorization checks without a clinical and engineering plan could introduce new hazards. The answer cannot be permanent vendor captivity, either. A dependency that only one company can administer is secure against some attackers while dangerously exposed to that company's disappearance.

The useful design question is how to transfer responsibility without transferring arbitrary power. Consider a proposed continuity arrangement in which validated service documentation, compatible programming tools, and necessary software are held by an independent custodian. Release conditions would be defined in advance, qualified maintainers would receive access, and each intervention would be recorded. This is a design proposal, not an assertion that escrow alone solves the problem. A file in escrow is worthless if the hardware, expertise, or legal permission to use it is missing.

The financial side has to be just as concrete. A promise of lifetime support needs an operational meaning: whose lifetime, which services, which component availability, and which organization pays after the original manufacturer stops trading? One practical procurement test would require a funded transition plan for predictable support obligations. The amount and mechanism would depend on the device and jurisdiction. The principle is simpler than the financing: obligations created in a person's body should not evaporate when a balance sheet changes.

Researchers studying post-trial access have also examined the perspectives of people using implanted neural devices and the investigators responsible for them. Their work places maintenance, cost, and continued access inside the research relationship. That matters because the end of a study is an administrative event. It is not necessarily the end of a participant's benefit from the device. A trial can finish successfully while leaving the participant with a difficult future that the published outcome measure never captures.

There is a distinction here between bodily autonomy and technical self-sufficiency. A person should not have to become a firmware engineer to retain agency over their treatment. Nor should the ability to refuse an intervention depend on their ability to build a replacement system. Autonomy needs a usable route to independent advice, an understandable account of the choices, and a way to disagree without losing all support. Ownership language does little if every practical option still leads back to one locked service portal.

An engineering review should therefore include the disappearance test. Remove the original vendor from the scenario. Can an authorized clinical team still interpret the device's state? Can it obtain consumables, preserve useful settings, identify a security defect, and explain the choices to the wearer? Where the answer is no, the dependency needs to be visible before implantation. This proposed test does not guarantee safety. It makes a concealed business assumption available for scrutiny while there is still time to change the design.

The most revealing failure may be an external component that costs a fraction of the implanted system. A cable, charger, or software entitlement can become the single point through which an organization holds the rest of the system together. Good engineering would identify those points and create workable substitutes or successor support. A device's sophistication is no excuse for letting its continuity depend on an accessory nobody thought important enough to preserve.

The practical measure of progress is not whether the industry promises to care. It is whether a wearer can discover, before committing, who will keep the system working under adverse conditions and who can authorize a transition. The implant may become part of a life. The company remains a company. A responsible architecture has to survive that difference.